Participants were randomized to DTaP@-IPV-Hib-HepB plus PCV@ , DTaP@-IPV-Hib-HepB with PCV@ administered @ month later or a pentavalent DTaP@-IPV/Hib plus HepB plus PCV@ at @ months of age in a randomized , open-label , phase IIb clinical trial .